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Abstract
Despite improving childhood coverage of the measles-mumps-rubella vaccine (MMR) in Victoria during the 1990s,
mumps and rubella notifications in age groups eligible for vaccination persisted. This study reviewed the mumps
and rubella surveillance data from 1993 to 2000 with a specific focus on method of diagnosis. There were 474
notifications of mumps over the seven-year period (annual median 61, range 40 to 77) and 3,544 notifications of
rubella (annual median 297, range 66 to 1,165). The highest notifications rates for mumps were consistently among
the 1–4 and 5–9 year age groups, whereas there was a marked change in the age distribution of rubella notifications
during this interval. A large rubella outbreak occurred in 1995 with 1,165 notifications; the highest notification
rates were males aged 15–24 years, infants under one year of age (males and females), and those aged 5–14 years
(males and females), respectively. The susceptibility of 5–24 year olds reflects historical changes to the Australian
Standard Vaccination Schedule. Rubella notifications returned to baseline levels in 1998 with the highest
notification rates in infants aged under one year, and children aged 1–4 years. For both mumps and rubella, the
majority of notifications for all age groups were clinically diagnosed, and were most common in children. Commun
Dis Intell 2003;27:94–99.
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Introduction
Measles, mumps and rubella were common viral
infections in childhood during the pre-vaccine era.
Mumps causes aseptic meningitis in up to 10 per cent
of cases and was the leading cause of viral
encephalitis prior to the implementation of vaccination
programs.1 Whilst acute rubella infection is usually
mild, antenatal infection can result in miscarriage,
foetal death, and congenital rubella syndrome.2
In Australia, monovalent vaccines for measles and
rubella were first available 30 years ago, with a
monovalent mumps vaccine available for at least
20 years (Table 1).3 In 1989 a trivalent measles,
mumps and rubella vaccine became available and a
two-dose schedule has been recommended in the
Australian Standard Vaccination Schedule for both
males and females since 1993.3
Despite improving MMR vaccination coverage in
Victorian children aged 2 years (from 78% in 1994–954
to 92% in 20005), a review of measles epidemiology
between 1992 and 1996 demonstrated continuing
high rates of notification in children, with the majority
of these based on clinical diagnosis alone.6 Enhanced
measles surveillance in Victoria since 1997 has shown
that a clinical diagnosis of measles has a low positive
predictive value, overestimating disease incidence,
particularly in young children eligible for vaccination.7
Surveillance of mumps and rubella during the 1990s
showed persisting levels of notifications from age
groups who should have been protected by high and
improving vaccination coverage rates. To gain a better
understanding of the epidemiology of mumps and
rubella, surveillance data from 1993 to 2000 were
reviewed, with a specific focus on the methods of
diagnosis employed.
Methods
Data source
The Victorian 1990 Health (Infectious Disease)
Regulations require medical officers and laboratories
to notify cases of mumps and rubella to the Department
of Human Services within 7 days of diagnosis. The
notification form included notifier details, the notified
disease, onset date and demographic data of the
cases. Notification data were electronically stored in
a computer database. Notifications received from
laboratories were classified as being laboratory
confirmed.
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Case definitions
The National Health and Medical Research Council
surveillance case definitions for mumps and rubella
during the period under review are shown in the
Box.8 Notifications were not routinely checked to
ascertain whether cases met the clinical criteria of
the National Health and Medical Research Council
definition.
Data analysis
All notifications of mumps and rubella received by
the Department of Human Services between
1 January 1993 and 31 December 2000 were collated
and analysed using MS Excel and Epi Info version
6.04d.
Age- and sex-specific annual notification rates were
calculated using Victorian mid-year population data
from the Australian Bureau of Statistics. Rates were
calculated for total notifications and laboratory-
confirmed notifications for both diseases. Rates
were calculated using the date of notification as the
date of onset was not available for all notifications.
For rubella sex- and age-specific laboratory-
confirmed rates in an outbreak year (1995) were
compared with a non-outbreak period when the
number of notifications was at an all time low (1998
to 2000). Age groups used for analysing each
disease were decided on by identifying changes in
local epidemiology and vaccination policy (Table 1).
For notifications in the year 2000 for children aged
1–4 years the MMR immunisation status was
retrieved from the Australian Childhood Immunisation
Register (ACIR).
Results
Mumps
There were 474 mumps notifications received by the
Victorian Department of Human Services between
1 January 1993 and 31 December 2000. The median
number of annual notifications was 61 (range 40 to
77). There was no seasonal variation. Only 15 per
cent of these notifications were laboratory confirmed
(Figure 1).
The highest notification rates were seen in the
1–4 years age group (average annual rate 5.7 per
100,000 population, range 4.3 to 7.7 per 100,000
population) and those aged 5–9 years (average annual
rate 5.6 per 100,000 population, range 2.5 to 8.6 per
100,000 population) (Table 2, Figure 2).
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Box. National Health and Medical Research Council case definitions for mumps and
rubella, 1994
Mumps
• The mumps virus isolated from a clinical specimen; OR
• a significant rise in mumps antibody level by any standard serological assay, except following
immunisation; OR
• a clinically compatible illness (unilateral or bilateral swelling of the parotid or other salivary glands
lasting two days or more without other apparent cause).
Rubella
A generalised maculopapular rash and a fever, plus:
• one or more of arthralgia/arthritis, lymphadenopathy and conjunctivitis, plus
• an epidemiological link to a confirmed case; OR
• a demonstrated rubella-specific IgM antibody, except following immunisation; OR
• a fourfold or greater change in rubella antibody titre between acute and convalescent phase sera
obtained at least two weeks apart; OR
• rubella virus isolated from a clinical specimen.
Figure 1. Annual notifications of mumps,
Victoria, 1993 to 2000, by notification
type
Between 1993 and 2000 there were no laboratory-
confirmed notifications in infants aged under one year.
The proportion of laboratory-confirmed notifications
increased with age, reaching a maximum of 37 per
cent for those aged 20 years and above (Table 2).
In 2000, there were 11 notifications in the 1–4 years
age group and all were clinically diagnosed. According
to the ACIR, 10 cases had received their first MMR
vaccination due at 12 months.
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Table 1. Significant events in measles, mumps and rubella immunisation practice in Australia
Year Intervention
1968 Live, attenuated measles vaccine approved
1970 Rubella vaccine approved, measles vaccine widely available
1971 Measles vaccine initially recommended for 15-month-old infants
School girl rubella program for 10–14 year old girls and non-immune women of child-bearing
age
1975 First national immunisation schedule: measles vaccination for infants at 12 months of age
1980 Mumps vaccine approved for infants aged 12–15 months
1982 Combined measles-mumps vaccine (MM) available
1989 Measles-mumps-rubella vaccine (MMR) available
1993 Childhood immunisation schedule included 2nd dose of MMR for children aged 10–16years (MMR replaced the school girl rubella vaccination program)
1998 Measles Control Campaign with shift in timing of 2nd dose to children aged 4–5 years
2000 Recommended age for 2nd MMR dose changed to 4 years
Adapted from historical table available at http://www.ncirs.usyd.edu.au/publ/publ-79-histtab3.html
Figure 2. Mumps notification rates per 100,000
population, Victoria, 1993 to 2000, by
age group
Table 2. Laboratory and clinical notifications of mumps, Victoria, 1993 to 2000, by age group
Age group Clinical only Laboratory confirmed Total Average annual
rate (per 100,000
population)n % n % n
<1 11 (100) 0 (0) 11 2.3
1–4 112 (97) 4 (3) 116 5.7
5–9 136 (94) 8 (6) 144 5.6
10–19 72 (83) 15 (17) 87 1.7
20+ 73 (63) 43 (37) 116 0.4
Total 404 (83) 70 (17) 474 1.3
Rubella
There were 3,544 rubella notifications received by
the Victorian Department of Human Services between
1 January 1993 and 31 December 2000 (Figure 3),
with 2 outbreaks of rubella identified. Figure 3 includes
the tail end of an outbreak that commenced in 1992
and concluded in 1993. The second outbreak began
in mid-1995, peaked quickly (1,165 notifications
received in 1995), with notifications declining, but
remaining above pre-1995 baseline levels until 1998.
Notifications declined from 189 in 1998, to 123 in
1999 and to 66 in 2000, which was the lowest annual
figure on record (Figure 3).
Laboratory-confirmed notifications, as a proportion
of all notifications, were highest during the 1995
outbreak reaching 52 per cent in males and 38 per
cent in females (Figure 3, Table 3). This proportion
decreased to 16 per cent in males and 14 per cent in
females for the period between 1998 and 2000. For
both 1995 and the period between 1998 and 2000,
the proportion of notifications that were laboratory-
confirmed was lower in the younger age groups
compared with older age groups (Table 3). In 1995
the highest notification rates were in males aged
15–24 years (153 cases per 100,000 population),
male and female infants combined aged under one
year (98 cases per 100,000 population), and male
and females combined aged 5–14 years (38 cases
per 100,000 population) (Table 3, Figure 4).
In 1995 the male to female ratio for all notifications in
the 15–24 year age range was 14.5:1 but had fallen
to 4:1 between 1998 and 2000. In contrast, the male
to female ratio for those aged 5–14 years remained
relatively unchanged (1.4:1 in 1995 and 1.8:1 between
1998 and 2000). Between 1998 and 2000 (non-
outbreak period) the highest notification rate was in
infants aged under one year and second highest in
the 1–4 year age group (Table 3, Figure 4).
In the year 2000 there were 24 notifications in children
aged 1–4 years; 23 were clinically diagnosed (19 had
received at least one dose of MMR vaccination
according to the ACIR) and one was laboratory
diagnosed (no doses of MMR according to the ACIR).
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Figure 3. Annual notifications of rubella,
Victoria, 1993 to 2000, by notification
type
Figure 4. Notification rates for rubella per
100,000 population, Victoria, 1993 to
2000, by age group
Table 3. Notification rates for rubella per 100,000 population, Victoria, 1995 (annual rate) and 1998
to 2000 (average annual rate), by age group, sex and proportion that were
laboratory-confirmed
1995 1998 to 2000
Age group Male Female Male Female
Rate LC
%
Rate LC
%
Rate LC
%
Rate LC
%
<1 110.6 19 84.3 8 59.0 0 45.4 0
1–4 38.1 0 32.1 8 13.8 5 12.2 2
5–14 42.7 42 32.3 37 5.3 2 3.0 15
15–24 153.2 56 10.9 50 5.6 42 1.5 25
25+ 11.3 69 2.9 73 0.7 47 0.3 55
Total 40.5 52 10.7 38 3.5 16 2.0 14
LC Laboratory-confirmed
Discussion
This review of Victorian surveillance data between
1993 and 2000 demonstrated little change in mumps
epidemiology with notification rates, the proportion of
laboratory-confirmed cases, and age groups
affected remaining stable. The mumps notification
rates were highest in the 1–4 and 5–9 year age
groups. The rubella surveillance data, by contrast,
demonstrated a changing epidemiology. A large
rubella outbreak occurred in 1995 with the highest
notification rates in males aged 15–24 years, infants
under one year of age (males and females), and
those aged 5–14 years (males and females),
respectively. By 1998 rubella notifications had
returned to pre-1995 baseline levels. The highest
rubella notification rates between 1998 and 2000
were seen in infants aged under one year, with the
second highest rates in the 1–4 year age group. For
both mumps and rubella, laboratory confirmation in
these younger age groups was infrequent. A similar
picture has been seen for measles where it was
demonstrated that the low rate of laboratory
confirmation for notifications from the younger age
groups represented a true absence of disease.7 On
the basis of this, we hypothesise that low rates of
laboratory-confirmed mumps and rubella are indicative
of low levels of disease.
Enhanced measles surveillance introduced for Victoria
in 1997 has shown that passive surveillance based
on the clinical diagnosis of measles was inaccurate
due to the poor predictive value of a clinical diagnosis.
Of 317 notifications, 258 had serology performed
and only 19 (6%) of these were laboratory confirmed
with measles.7 Similarly, in populations with high
levels of MMR coverage simple rash illnesses
(diagnosed as rubella) and parotitis (a classical feature
of mumps) may often be due to other aetiologies.9,10
In this study, a large proportion of notifications for
both mumps and rubella were from children in age
groups targeted by vaccination and were based on a
clinical diagnosis only, which may have resulted in an
overestimation of cases. This has been highlighted by
other enhanced surveillance systems in countries
with widespread vaccination. Enhanced mumps
surveillance in the United Kingdom11 and Texas12
showed that despite a large proportion of notified
cases being laboratory tested only 3 per cent and
7 per cent, respectively, were laboratory confirmed.
Rubella enhanced surveillance during the National
England and Wales measles and rubella immunisation
strategy campaign in 1994 showed only 29 per cent
of notified cases were laboratory confirmed as
rubella.13
The higher rubella notification rates in the 5–14 and
15–24 year age ranges, reflect susceptibility due to
lack of exposure to the virus in childhood and lack of
vaccination due to changes in the schedule. Infant
rubella vaccination (as part of MMR) was only
available from 1989 and the second dose strategy for
teenagers commenced in Victoria in 1994/95.14 The
national serosurvey performed prior to the 1998
Measles Control Campaign showed the 10–12 year
age group had the lowest proportion of immune
subjects (60%) but this gap in immunity was removed
by the Campaign.14 Rubella vaccination between
1971 and 1993 targeted adolescent schoolgirls only,
leaving contemporary males susceptible.14,15 Prior to
the Measles Control Campaign, females had
significantly higher rubella seropositivity rates (97%)
than males (85%) in the 16–39 year age range.14
High vaccine coverage in children should continue to
ensure minimal mumps and rubella virus circulation in
the younger age groups. Continuing rubella circulation
will result in cases in males currently aged in their
20s15 and for mumps it is likely that true cases will
also be in adults. As has been seen with measles
epidemiology, gradual introduction of vaccination
programs with slowly increasing coverage rates leads
to the development of susceptible cohorts, who neither
get wild virus infection nor receive vaccination.16
This study highlights the difficulties in interpreting
notifications rates derived from passive surveillance
data as the incidence of vaccine preventable diseases
declines. To gain a better understanding of the true
epidemiology of mumps and rubella in Victoria the
Department of Human Services is undertaking a
period of enhanced surveillance for mumps and
rubella. The system will be similar to that introduced
for measles in 1997,7 focussing on laboratory
confirmation of all cases. Early results from enhanced
mumps surveillance have shown that of 16 notifications
made in July 2001, only two were laboratory
confirmed.17 These results suggest mumps, at least,
is less common than notifications would lead us to
believe.
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